Tarceva is indicated for the treatment of patients with locally advanced or metastatic Non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. In the pivotal clinical trial for NSCLC, there was a significant survival benefit for a large, unselected group of patients receiving Tarceva monotherapy. Tarceva significantly improved overall survival by 37% vs placebo in these pretreated NSCLC patients (HR=0.73; 95% CI=0.61-0.86; P<0.001).

You can find information on additional clinical trials of Tarceva (erlotinib) by visiting ClinicalTrials.gov

The Food and Drug Administration (FDA) approved Tarceva for advanced Non-Small Cell Lung Cancer on November 18, 2004. For more information see the FDA Approval Letter.

Tarceva is a pill taken by mouth once a day to treat your cancer. Tarceva is used for patients with advanced NSCLC who have received at least one previous chemotherapy regimen that did not work. Take Tarceva at least one hour before or two hours after eating.

rEEG® is a useful guide in all psychiatric and addiction patients, regardless of their diagnosis, except primary psychosis. Though the treatment database does not currently account for patients with primary psychotic disorders, or contain the antipsychotic medications, a future study is expected to address these patients. rEEG® has been most frequently used in patients with depressive disorders, bipolar disorder, anxiety disorders, ADHD, eating disorders, and substance abuse disorders.

Yes, see the Keller and Butcher book, Assessment of Chronic Pain Patients With the MMPI-2 (University of Minnesota Press). This book is available from Pearson.

Individuals appropriate for treatment in an acute physical rehabilitation program include those disabled as a result of chronic illness such as post-stroke conditions, congestive heart failure, acute arthritis, multiple sclerosis, Parkinson's and other degenerative diseases; those disabled as a result of major, multiple trauma including people with complex orthopedic conditions, burns, brain and spinal cord damage and amputation and those disabled by premature birth or congenital defects.

Children or adolescents who are actively suicidal, have multiple prior psychiatric hospitalizations, or are experiencing seizures should be seen by an appropriate sub specialist.

Tarceva is an FDA-approved targeted cancer therapy clinically proven to help some NSCLC patients live significantly longer. In addition to improving survival, Tarceva may slow or stop the growth of cancer - and may even shrink the tumors in some patients. Tarceva is convenient to take; it's a pill you take by mouth once a day as prescribed by your doctor. Individual results may vary. Though individual results may vary, Tarceva has been shown to help some patients live longer.

Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Results from two multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy, and its use is not recommended in that setting.

Since food substantially increases the bioavailability of erlotinib and may increase the risk of adverse events, patients should be instructed to take Tarceva at least one hour before or two hours after the ingestion of food. The degree that food increases the bioavailability of erlotinib may vary; therefore, Tarceva tablets should be taken on an empty stomach to help ensure that patients obtain consistent plasma levels of the drug.

HeartScore?? is developed for the primary prevention of cardiovascular disease and it may be used with all male and female patients between 40 and 65 that you see in your clinic. The HeartScore?? web-based program may be used in cases where there is doubt as to whether one patient has a high risk of developing a cardiovascular disease, or if the patient requires an overview of his risk profile and suggestions on how it can be changed.

Your health care provider will likely review with you the activities they feel are appropriate for your condition. In general, heart failure patients can tolerate symptom limited activities, meaning that walking or partaking in physical activity is safe and actually beneficial as long as you do not become symptomatic during the activity.

You can find information on additional clinical trials of Tarceva (erlotinib) by visiting ClinicalTrials.gov

First of all, there is no average shift.

Our Lady of Peace Hospital admits medically complex patients. Examples of conditions and diagnoses that are treated are patients with respiratory failure, requiring ventilator management, post surgical patients, prolonged IV antibiotics, wounds, and patients with renal disease requiring dialysis.

Initial government funded research and development work in cardiac-support systems in 1966. The company began clinical trials of the air-driven LVAS in 1986 and of the electric system in 1991. It has been used in patients ranging from age 11 to 78, with an average age of 51. The HeartMate device has been implanted in more than 4,100 patients at leading cardiac centers in the U.S. and overseas.

RENOVA should only be used under medical supervision as part of a total skin care and sun protection program. It should not be used by individuals with a history of sensitivity reactions to any of its components, and should be discontinued if hypersensitivity to any of its ingredients is noted. RENOVA should not be used by people taking drugs known to be photosensitizers, or by pregnant women, women attempting to become pregnant or in women at high risk of pregnancy.

Yes. CoagCare offers secure access from anywhere with internet access. We have even had patients who communicated with their physician while on a cruise!

Every whole blood donation can help save up to three lives. This is accomplished because the donation is separated into three separate components:

Tissue is used in a wide range of vital medical procedures, including grafting skin for burn victims, replacing defective heart valves, saving limbs following tumor surgery, reconstructing hip and knee joints and enhancing spinal fusion.

Yes. The FACT-G (the general version), created specifically for cancer patients, has been validated in HIV disease, multiple sclerosis, and even the general population (with minor modifications). Other FACIT questionnaires have to varying degrees been tested in different groups, so it is best to ask on a scale-by-scale basis.

Tarceva is a targeted cancer treatment. Unlike many traditional chemotherapies, Tarceva affects certain cancer cell activities. Tarceva is designed to block tumor cell growth by targeting the protein in your body called the Human Epidermal Growth Factor Receptor 1 (HER1/EGFR). This protein is important for tumor cell growth in NSCLC.

If you have locally advanced or metastatic NSCLC and have received at least one chemotherapy regimen that has not worked, you may be a candidate for Tarceva. Speak with your doctor about whether Tarceva is right for you.